{"entity":{"id":"gadobenate-dimeglumine","kind":"drug","name":"Gadobenate dimeglumine","aka":["gadobenate","gadobenic acid","MultiHance"],"tldr":"An MRI dye given into a vein for scans of the brain and spine and for imaging blood vessels.","summary":"Bracco's MultiHance (NDA 021357, first approved 23 November 2004) is indicated for MRI of the central nervous system \"to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues\" and for MR angiography of renal and aorto-ilio-femoral vessels. ATC V08CA08 (gadobenic acid). Like every gadolinium-based contrast agent in the United States, its label carries a boxed warning on the risks of intrathecal use and nephrogenic systemic fibrosis, a thickening of skin and organs seen in people with severe kidney disease.","status":"approved","asOf":"2026-11-04","links":[{"label":"Drugs@FDA MultiHance (NDA 021357)","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021357"},{"label":"DailyMed label: MultiHance","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59077a3e-5f03-4342-ae24-856267545631"},{"label":"WHO ATC index V08CA: paramagnetic contrast media","url":"https://atcddd.fhi.no/atc_ddd_index/?code=V08CA&showdescription=no"}],"tags":["contrast-agents-gaps-2026-11","diagnostic"],"related":[],"cancers":["glioblastoma","secondary-brain-tumours"],"sections":[],"technologies":["gadolinium-based-contrast-agents","mri"],"targets":[],"drugs":[],"companies":["bracco"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo contrast agent gap fill (Drugs@FDA, FDA labels, DailyMed, EMA register, WHO ATC index)","editedOn":"2026-11-04"},"brand":"MultiHance","modality":"Gadolinium-based contrast agent for MRI (intravenous)","mechanism":"A gadolinium chelate that shortens proton relaxation times and brightens tissue on MRI where it leaks from blood vessels.","approvals":[{"region":"US","year":2004,"indication":"MRI of the central nervous system; MR angiography of renal and aorto-ilio-femoral vessels","note":"NDA 021357; Bracco"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gadobenate-dimeglumine/","neighbours":{"cancer":[{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"gadolinium-based-contrast-agents","kind":"technology","name":"Gadolinium-based and other MRI contrast agents","route":"/technologies/gadolinium-based-contrast-agents/"},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/"}],"company":[{"id":"bracco","kind":"company","name":"Bracco (Bracco Imaging and Bracco Diagnostics)","route":"/companies/bracco/"}]}}